WuXi Biologics, a wholly owned subsidiary of WuXi AppTec, and Prima BioMed, an immuno-oncology company, announced on March 2, 2016 that through a strategic supply partnership, Prima s immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi s cGMP facility in ChinOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.